Positive Clinical Study Results, New Product Launches, and Leadership Changes - Research Report on Allergan, Isis, Covidien, BD, and DaVita HealthCare Partners Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, June 27, 2013 NEW YORK, June 27, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Allergan, Inc. (NYSE: AGN), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), Covidien plc (NYSE: COV), Becton, Dickinson and Co. (NYSE: BDX) and DaVita Healthcare Partners Inc. (NYSE: DVA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Allergan, Inc. Research Report On June 24, 2013, Allergan, Inc. (Allergan) announced that David E.I. Pyott, Chairman of the Board and Chief Executive Officer of Allergan, and the Company's Board of Directors, have named Douglas S. Ingram as President of Allergan. Ingram will lead Allergan's global commercial operations, with responsibility for the Company's broad portfolio of pharmaceutical, consumer, and medical device products, including its leading ophthalmology products (e.g. RESTASIS, LUMIGAN, ALPHAGAN, COMBIGAN, GANFORT, OPTIVE and OZURDEX), facial aesthetics products (e.g. BOTOX and JUVÉDERM), and medical dermatology products (e.g. ACZONE). Allergan stated that Ingram has been with the Company for 17 years, and for the past three years, Ingram has served as the Company's Executive Vice President and President, Europe, Africa and Middle East (EAME), where he was responsible for Allergan's regional pharmaceutical and medical device operations, with a focus on strategic planning, sales and marketing, development and general management. Full Research Report on Allergan, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/1c25_AGN] -- ISIS Pharmaceuticals, Inc. Research Report On June 23, 2013, ISIS Pharmaceuticals Inc. (Isis) announced data from Phase 2 study of ISIS-APOCIII in patients with high triglycerides and type 2 diabetes. In the study, patients treated with ISIS-APOCIII experienced an 88% reduction in apolipoprotein C-III (apoC-III), a 72% reduction in triglyceride levels, a 40% increase in high-density lipoprotein cholesterol (HDL-C), the 'good' cholesterol, and improvements in other atherogenic lipid parameters. Further, patients dosed with ISIS-APOCIII[Rx] showed consistent trends towards enhanced insulin sensitivity with improvements in multiple measures of glucose control. The Company also stated that it is evaluating ISIS-APOCIII in a separate Phase 2 study in patients with moderate to high triglycerides and expects to report data from the study in the summer of 2013. The Full Research Report on ISIS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/f5f5_ISIS] -- Covidien plc Research Report On June 20, 2013, Covidien plc (Covidien) announced that an independent study called CLOTS 3, conducted by the University of Edinburgh, successfully demonstrated the effectiveness of Covidien's Kendall SCD system with Vascular Refill Detection Technology on immobile stroke patients. The study showed a 29.9% decrease in the development of proximal deep vein thrombosis (DVP) in immobile stroke patients who received intermittent pneumatic compression (IPC) using the Kendall SCD system with Vascular Refill Detection Technology, which as per the Company, delivers sequential, circumferential, gradient compression through thigh-length sleeves. Compared to the routine care group, the IPC group showed a 14% mortality risk reduction (p = 0.042) during the first six months after admission for stroke. The results of the CLOTS 3 trial were presented at the European Stroke Conference and were also published in the medical journal, The Lancet. The Full Research Report on Covidien plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/a748_COV] -- Becton, Dickinson and Co. Research Report On June 24, 2013, BD Diagnostics, a segment of Becton, Dickinson and Co. (BD), together with Diagenode SA, an international biotech company based in Belgium, announced the European-only launch of the Diagenode Bordetella pertussis/parapertussis real-time polymerase chain reaction (PCR) kit for use on the BD MAX System. According to the Company, Bordetella pertussis is responsible for 30-50 million annual cases of pertussis, or the "whooping cough." Timely detection of the infection through the PCR is essential in preventing the spread of disease and reducing the risk of widespread outbreaks. BD further stated that PCR testing is ideal in enabling the prompt differential diagnosis of pertussis from other respiratory diseases such as atypical pneumonia, bronchitis, or respiratory viruses. Through BD's collaborations with leading in vitro diagnostic (IVD) developers such as Diagenode, the Company is rapidly expanding its molecular testing menu by offering syndrome specific and clinically relevant IVD assays across a number of disease syndromes. The Full Research Report on Becton, Dickinson and Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/0978_BDX] -- DaVita Healthcare Partners Inc. Research Report On June 24, 2013, DaVita, the dialysis division of DaVita HealthCare Partners Inc. (DaVita HealthCare Partners), announced that it has selected Cureatr, the enterprise messaging and workflow navigation solution for healthcare, to enhance communication and care coordination for care teams at dialysis centers across the country. The Company said that Cureatr's mobile care coordination and reporting system will enable DaVita foster more robust clinical information sharing, which may help reduce costly hospital admissions. Also, it stated that this partnership allows DaVita to provide Cureatr's iPhone and web apps to thousands of facility administrators, care managers, nurses, and affiliated nephrologists. The Company also expects this to improve communication between DaVita's dialysis care teams, resulting in more efficient delivery of patient care.The Full Research Report on DaVita Healthcare Partners Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/548a_DVA] -- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Wall Street Reports Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Positive Clinical Study Results, New Product Launches, and Leadership Changes - Research Report on Allergan, Isis, Covidien, BD,
Press spacebar to pause and continue. Press esc to stop.